Clinical Trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Study acronym: KLK2-PASenger
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Protocol Amendment History 3 changes
notable Trial sites expanded: 117 -> 136 locations 2026-06-06
notable Trial sites expanded: 97 -> 117 locations 2026-05-12
notable Trial sites expanded: 53 -> 97 locations 2026-04-15
Trial Details
NCT Number NCT07225946
Lead Sponsor Janssen Research & Development, LLC
Conditions Prostatic Neoplasms, Castration-Resistant
Enrollment 800 participants
Start Date 2025-12-19
Primary Completion 2027-11-19 (estimated)
Study Completion 2029-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-05